Abbvie Inc., of North Chicago, Ill., initiated phase III clinical studies to evaluate efficacy and safety of an oral once-daily agent of ABT-493, a NS3/4A protease inhibitor and ABT-530, a NS5A inhibitor, for the treatment of genotype 1-6 chronic hepatitis C in Japanese patients.